David Rimm, Professor of Pathology, Yale University School of Medicine Bio and Contact Info
Listen (4:16) An unsexy science
Listen (5:36) A lack of certifications
Listen (6:20) Most pathologists not aware of the problem
Listen (2:48) Pathologists not reimbursed for providing research samples
Listen (7:44) Still no Tissue Quality Index
The next stop in our journey to better understand the impact of poor biospecimens on biomedical research takes us to Yale where we talk with pathology professor, David Rimm, about the new science of biospecimens.
In past interviews we’ve established the importance of better standards in the collection, handling and storage of biospecimens. David has developed some rare and unique training at Yale for the students of pathology, but still, he says that biospecimen science has not really taken off.
“Most scientists and pathologists are not aware of this problem,” says David, referring to the issue of sample degradation.
How is it the case that billions of dollars are spent studying samples that were not collected with any standards? Why are there no certifications for pathologists in this regard?
One thing that would help immensely and has been long hoped for is an assay that would tell whether a sample is still good, what David calls a Tissue Quality Index. Perhaps a researcher or pathologist does’t know where a sample came from or how long it’s been in storage. This Tissue Quality Index would be a scoring system for determining whether the sample could still be used for an application. David got a grant to develop the score, but didn’t quite get there with the one grant. He applied for another grant, but it was turned down. Regrettably, he says, it’s just not an important topic for traditional funders.
The holy grail of biospecimen science, a Tissue Quality Index, remains still to be grasped.
Podcast brought to you by: Quintiles - bringing people and knowledge together for a healthier world.